Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
Associated filings
- 19 Jul 22 25-NSE Exchange delisting
- 4 Oct 21 EFFECT Notice of effectiveness
- 1 Oct 21 POS AM Prospectus update (post-effective amendment)
- 8 Mar 21 424B3 Prospectus supplement
- 26 Feb 21 EFFECT Notice of effectiveness
- 26 Feb 21 424B3 Prospectus supplement
- 24 Feb 21 F-4/A Registration of securities (foreign) (amended)
-
19 Feb 21 F-4/A Registration of securities (foreign) (amended)
- 16 Feb 21 F-4/A Registration of securities (foreign) (amended)
- 28 Jan 21 F-4/A Registration of securities (foreign) (amended)
- 8 Jan 21 F-4/A Registration of securities (foreign) (amended)
- 25 Nov 20 F-4 Registration of securities (foreign)
LBPSW similar filings
Filing view
External links
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the use in this Amendment No. 4 to the Registration Statement (No.333-250986) on Form F-4 of 4D pharma plc of our report dated November 25, 2020, relating to the consolidated financial statements of 4D pharma plc, appearing in the Proxy Statement/Prospectus, which is part of this Registration Statement.
We also consent to the reference to our firm under the heading "Experts" in such Proxy Statement/Prospectus.
/s/ RSM US LLP
Boston, MA
February 19, 2021
1